Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy

2018/02/02 by Yingying Chen, Peng Liu, Xia Chen +3 · 17 citations
Medicine · #Potassium and Related Disorders #Dialysis and Renal Disease Management #Diabetes Treatment and Management

paper · doi:10.1016/j.amjms.2018.01.017

Citations

• A New Equation to Estimate Glomerular Filtration Rate

Cited by

• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA)
• Mitigating risk of aldosterone in diabetic kidney disease. [europepmc]
• Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. [europepmc]
• Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials. [europepmc]
• Clinical perspective-evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes. [europepmc]
• Development and Validation of a Model That Predicts the Risk of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients: A Cross-Sectional Study. [europepmc]
• American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. [europepmc]
• The association between dual RAAS inhibition and risk of acute kidney injury and hyperkalemia in patients with diabetic kidney disease: a systematic review and meta-analysis. [europepmc]
• Finerenone: Questions and Answers-The Four Fundamental Arguments on the New-Born Promising Non-Steroidal Mineralocorticoid Receptor Antagonist. [europepmc]
• Mineralocorticoid receptor antagonist use in chronic kidney disease with type 2 diabetes: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal Association (ERA). [europepmc]
• Angiotensin-converting-enzyme inhibitors and angiotensin receptor blockers for preventing the progression of diabetic kidney disease. [europepmc]
• Effects of xenogeneic transplantation of umbilical cord-derived mesenchymal stem cells combined with irbesartan on renal podocyte damage in diabetic rats. [europepmc]
• A real-world pharmacovigilance analysis of adverse events associated with irbesartan using the FAERS and JADER databases. [europepmc]
• The beneficial effect of gamma aminobutyric acid on diabetic nephropathy in type 2 diabetic rat model and their offspring. [europepmc]
• The nonsteroidal MR antagonist finerenone reverses Western diet-induced kidney disease by regulating mitochondrial and lipid metabolism and inflammation. [europepmc]
• Navigating Disparities and Overcoming Barriers to Access Diabetic Kidney Disease Therapies: A Proposed Multifactorial Approach. [europepmc]
• Mineralocorticoid receptor antagonists and mortality in hypertension: a systematic review and meta-analysis. [europepmc]